SC83288 is a clinical development candidate for the treatment of severe malaria

Pegoraro, S. et al. (2017) SC83288 is a clinical development candidate for the treatment of severe malaria. Nature Communications, 8, 14193. (doi: 10.1038/ncomms14193) (PMID:28139658) (PMCID:PMC5290327)

[img]
Preview
Text
147978.pdf - Published Version
Available under License Creative Commons Attribution.

2MB

Abstract

Severe malaria is a life-threatening complication of an infection with the protozoan parasite Plasmodium falciparum, which requires immediate treatment. Safety and efficacy concerns with currently used drugs accentuate the need for new chemotherapeutic options against severe malaria. Here we describe a medicinal chemistry program starting from amicarbalide that led to two compounds with optimized pharmacological and antiparasitic properties. SC81458 and the clinical development candidate, SC83288, are fast-acting compounds that can cure a P. falciparum infection in a humanized NOD/SCID mouse model system. Detailed preclinical pharmacokinetic and toxicological studies reveal no observable drawbacks. Ultra-deep sequencing of resistant parasites identifies the sarco/endoplasmic reticulum Ca(2+) transporting PfATP6 as a putative determinant of resistance to SC81458 and SC83288. Features, such as fast parasite killing, good safety margin, a potentially novel mode of action and a distinct chemotype support the clinical development of SC83288, as an intravenous application for the treatment of severe malaria.

Item Type:Articles
Additional Information:The research leading to these results has received funding from the Bundesministerium für Bildung und Forschung under the portfolio of the German Centre for Infectious Research (DZIF), the Wellcome Trust (grant number 098051), the Australian Research Council (grant number LP120200557), and the European Commission under the portfolio of the FP6-integrated project AntiMal (contract number LSHP-CT-2005-0188) and the 7th framework Center of Excellence EVIMalaR. Erratum: http://eprints.gla.ac.uk/203728/
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Otto, Dr Thomas
Authors: Pegoraro, S., Duffey, M., Otto, T. D., Wang, Y., Rösemann, R., Baumgartner, R., Fehler, S. K., Lucantoni, L., Avery, V. M., Moreno-Sabater, A., Mazier, D., Vial, H. J., Strobl, S., Sanchez, C. P., and Lanzer, M.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Nature Communications
Publisher:Nature Publishing Group
ISSN:2041-1723
ISSN (Online):2041-1723
Published Online:31 January 2017

University Staff: Request a correction | Enlighten Editors: Update this record